Patent · US Active

Crystalline form

US8809340B2 · kind B2 · utility

2Cited by
0References
13Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 12, 2013
Grant dateAug 19, 2014
Priority date
Expiry dateMar 12, 2033

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P43/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

This invention relates to a new crystalline form of the succinate salt of the epithelial sodium channel (ENaC) blocker 3-(3-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carbonyl}-benzenesulfonylamino)-propionic acid dipropylcarbamoylmethyl ester, pharmaceutical compositions comprising said crystalline form, uses of said crystalline form and pharmaceutical compositions, and methods for preparing said crystalline form.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.